Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 421

1.

Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives.

Pontali E, Raviglione MC, Migliori GB; and the writing group members of the Global TB Network Clinical Trials Committee.

Eur Respir Rev. 2019 May 29;28(152). pii: 190035. doi: 10.1183/16000617.0035-2019. Print 2019 Jun 30.

2.

Effectiveness of interventions for reducing TB incidence in countries with low TB incidence: a systematic review of reviews.

Collin SM, Wurie F, Muzyamba MC, de Vries G, Lönnroth K, Migliori GB, Abubakar I, Anderson SR, Zenner D.

Eur Respir Rev. 2019 May 29;28(152). pii: 180107. doi: 10.1183/16000617.0107-2018. Print 2019 Jun 30. Review.

3.

Analysis of loss to follow up in 4,099 multidrug-resistant pulmonary tuberculosis patients.

Walker IF, Shi O, Hicks J, Elsey H, Wei X, Menzies D, Lan Z, Falzon D, Migliori GB, Pérez-Guzmán C, Vargas MH, García-García L, Sifuentes Osornio J, Ponce-De-León A, van der Walt M, Newell JN.

Eur Respir J. 2019 May 9. pii: 1800353. doi: 10.1183/13993003.00353-2018. [Epub ahead of print]

PMID:
31073080
4.

Tuberculosis series 2019.

Silva DR, Migliori GB, Mello FCQ.

J Bras Pneumol. 2019 Apr 25;45(2):e20190064. doi: 10.1590/1806-3713/e20190064. English, Portuguese. No abstract available.

5.

Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?

Velizarova S, Gabrovska N, Spasova A, Marais B, Harausz EP, Tiberi S, Migliori GB, Manissero D.

J Bras Pneumol. 2019 Apr 25;45(2):e20190043. doi: 10.1590/1806-3713/e20190043. English, Portuguese. No abstract available.

6.

International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis.

Migliori GB, Centis R, D'Ambrosio L, Silva DR, Rendon A.

J Bras Pneumol. 2019 Apr 25;45(2):e20180420. doi: 10.1590/1806-3713/e20180420. English, Portuguese.

7.

Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation.

Tiberi S, Torrico MM, Rahman A, Krutikov M, Visca D, Silva DR, Kunst H, Migliori GB.

J Bras Pneumol. 2019 Apr 25;45(2):e20180324. doi: 10.1590/1806-3713/e20180324. Review. English, Portuguese.

8.

Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.

Migliori GB, Nardell E, Yedilbayev A, D'Ambrosio L, Centis R, Tadolini M, van den Boom M, Ehsani S, Sotgiu G, Dara M.

Eur Respir J. 2019 Jun 5;53(6). pii: 1900391. doi: 10.1183/13993003.00391-2019. Print 2019 Jun.

PMID:
31023852
9.

Recent evidence on delamanid use for rifampicin-resistant tuberculosis.

Pontali E, Centis R, D'Ambrosio L, Toscanini F, Migliori GB.

J Thorac Dis. 2019 Mar;11(Suppl 3):S457-S460. doi: 10.21037/jtd.2018.11.26. No abstract available.

10.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

11.

Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.

Visca D, Zampogna E, Sotgiu G, Centis R, Saderi L, D'Ambrosio L, Pegoraro V, Pignatti P, Muňoz-Torrico M, Migliori GB, Spanevello A.

Eur Respir J. 2019 Mar 14;53(3). pii: 1802184. doi: 10.1183/13993003.02184-2018. Print 2019 Mar. No abstract available.

PMID:
30872556
12.

Prioritising children and adolescents in the tuberculosis response of the WHO European Region.

Gröschel MI, van den Boom M, Migliori GB, Dara M.

Eur Respir Rev. 2019 Mar 14;28(151). pii: 180106. doi: 10.1183/16000617.0106-2018. Print 2019 Mar 31. Review.

13.

Another aetiology for tuberculosis-beyond the Mycobacterium.

Santos AP, Migliori GB.

Int J Tuberc Lung Dis. 2019 Mar 1;23(3):277. doi: 10.5588/ijtld.19.0076. No abstract available.

PMID:
30871656
14.

Launching the Global TB Network.

Rendon A, Silva DR, Esposito S, Sotgiu G, Migliori GB, Chakaya JM.

Int J Tuberc Lung Dis. 2019 Feb 1;23(2):123-124. doi: 10.5588/ijtld.18.0648. No abstract available.

PMID:
30808446
15.

Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA.

Nasiri MJ, Pormohammad A, Goudarzi H, Mardani M, Zamani S, Migliori GB, Sotgiu G.

Infection. 2019 Jun;47(3):353-361. doi: 10.1007/s15010-019-01285-7. Epub 2019 Feb 25. Review.

PMID:
30805899
16.

World Tuberculosis Day March 24th 2019 Theme: "It's TIME" - International Journal of Infectious Diseases Tuberculosis Theme Series.

Petersen E, Rao M, Ippolito G, Gualano G, Chakaya J, Ntoumi F, Moore D, Allen R, Gaskell K, Öhd JN, Hergens MP, Krishnamoorthy S, Ugarte-Gil C, Kirwan DE, Honeyborne I, McHugh TD, Köser CU, Kranzer K, Tiberi S, Migliori GB, Mao Q, Yang Y, Oliveira SP, Cardoso RF, Detjen A, Marais B, de Gijsel D, von Reyn CF, Goscé L, Abubakar I, Maeurer M, Zumla A.

Int J Infect Dis. 2019 Mar;80S:S1-S5. doi: 10.1016/j.ijid.2019.02.024. Epub 2019 Feb 23. No abstract available.

17.

Challenging MDR-TB clinical problems - The case for a new Global TB Consilium supporting the compassionate use of new anti-TB drugs.

Tiberi S, Pontali E, Tadolini M, D'Ambrosio L, Migliori GB.

Int J Infect Dis. 2019 Mar;80S:S68-S72. doi: 10.1016/j.ijid.2019.01.040. Epub 2019 Jan 25.

18.

Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.

Rosales-Klintz S, Bruchfeld J, Haas W, Heldal E, Houben RMGJ, van Kessel F, Mandelbaum M, Matteelli A, Migliori GB, Oordt-Speets A, Solovic I, Vašáková M, Verver S, de Vlas SJ, Vonk Noordegraaf-Schouten MJM, de Vries G, Zenner D, van der Werf MJ.

Eur Respir J. 2019 Jan 17;53(1). pii: 1802077. doi: 10.1183/13993003.02077-2018. Print 2019 Jan. No abstract available.

PMID:
30655449
19.

Delamanid: does it have a role in tuberculosis treatment?

Centis R, Sotgiu G, Migliori GB.

Lancet Respir Med. 2019 Mar;7(3):193-195. doi: 10.1016/S2213-2600(18)30455-7. Epub 2019 Jan 7. No abstract available.

PMID:
30630779
20.

ERS syllabus for postgraduate training in respiratory infections: a guide for comprehensive training.

Aliberti S, Farr A, Tabin N, Blasi F, Torres A, Woodhead M, Migliori GB, Sotgiu G, Dimopoulos G, Chalmers JD, Ringshausen FC, Loebinger MR, Read R, Rohde G.

Breathe (Sheff). 2018 Dec;14(4):269-275. doi: 10.1183/20734735.026218.

21.

The European Respiratory Society's 10 Principles for Lung Health.

Horváth I, Barry M, Brusselle G, Burghuber OC, Bush A, Robalo Cordeiro C, Gaga M, Gratziou C, Saraiva I, Stolz D, Troosters T, Welte T, Migliori GB, Joos G.

Eur Respir J. 2018 Nov 29;52(5). pii: 1801373. doi: 10.1183/13993003.01373-2018. Print 2018 Nov. No abstract available.

PMID:
30498051
22.

Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned.

Alffenaar JC, Tiberi S, Migliori GB.

Lancet Infect Dis. 2019 Jan;19(1):3-4. doi: 10.1016/S1473-3099(18)30549-8. Epub 2018 Nov 23. No abstract available.

PMID:
30477962
23.

Evolution of programmatic definitions used in tuberculosis prevention and care.

Migliori GB; Global Tuberculosis Network (GTN).

Clin Infect Dis. 2018 Nov 20. doi: 10.1093/cid/ciy990. [Epub ahead of print] No abstract available.

PMID:
30462170
24.

Research Needs on Respiratory Health in Migrant and Refugee Populations. An Official American Thoracic Society and European Respiratory Society Workshop Report.

Roman J, Viegi G, Schenker M, Ojeda VD, Pérez-Stable EJ, Nemery B, Annesi-Maesano I, Patel SR, La Grutta S, Holguin F, Moughrabieh A, Bime C, Lindberg A, Migliori GB, de Vries G, Ramírez J, Aliberti S, Feldman C, Celedón JC.

Ann Am Thorac Soc. 2018 Nov;15(11):1247-1255. doi: 10.1513/AnnalsATS.201807-478ST.

PMID:
30382778
25.

Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis.

Siddique AA, Schnitzer ME, Bahamyirou A, Wang G, Holtz TH, Migliori GB, Sotgiu G, Gandhi NR, Vargas MH, Menzies D, Benedetti A.

Stat Methods Med Res. 2018 Oct 31:962280218808817. doi: 10.1177/0962280218808817. [Epub ahead of print]

PMID:
30381005
26.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

27.

Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes.

Collin SM, de Vries G, Lönnroth K, Migliori GB, Abubakar I, Anderson SR, Zenner D.

Eur Respir J. 2018 Dec 6;52(6). pii: 1801449. doi: 10.1183/13993003.01449-2018. Print 2018 Dec.

PMID:
30309977
28.

Global TB Network: working together to eliminate tuberculosis.

Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito S, Migliori GB.

J Bras Pneumol. 2018 Set-Oct;44(5):347-349. doi: 10.1590/S1806-37562018000000279. English, Portuguese. No abstract available.

29.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
30.

European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations.

Migliori GB, Sotgiu G, Rosales-Klintz S, van der Werf MJ.

Eur Respir J. 2018 Nov 8;52(5). pii: 1801617. doi: 10.1183/13993003.01617-2018. Print 2018 Nov. No abstract available.

PMID:
30209200
31.

Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.

Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.

J Infect. 2019 Jan;78(1):35-39. doi: 10.1016/j.jinf.2018.08.003. Epub 2018 Aug 7.

PMID:
30096332
32.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
33.

Tuberculosis series.

Silva DR, Mello FCQ, Kritski A, Dalcolmo M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):71-72. doi: 10.1590/s1806-37562018000020001. English, Portuguese. No abstract available.

34.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Review. Portuguese, English.

35.

Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy.

Carvalho ACC, Cardoso CAA, Martire TM, Migliori GB, Sant'Anna CC.

J Bras Pneumol. 2018 Apr;44(2):134-144. doi: 10.1590/s1806-37562017000000461. Review. Portuguese, English.

36.

Eliminating tuberculosis in Latin America: making it the point.

Duarte R, Silva DR, Rendon A, Alves TG, Rabahi MF, Centis R, Kritski A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):73-76. doi: 10.1590/s1806-37562017000000449. English, Portuguese. No abstract available.

37.

Predictors of mortality among intensive care unit patients coinfected with tuberculosis and HIV.

Ferreira MD, Neves CPD, Souza AB, Beraldi-Magalhães F, Migliori GB, Kritski AL, Cordeiro-Santos M.

J Bras Pneumol. 2018 Apr;44(2):118-124. doi: 10.1590/s1806-37562017000000316. Portuguese, English.

38.

Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.

Abubakar I, Matteelli A, de Vries G, Zenner D, Cirillo DM, Lönnroth K, Popescu G, Barcellini L, Story A, Migliori GB.

Eur Respir J. 2018 May 10;51(5). pii: 1702604. doi: 10.1183/13993003.02604-2017. Print 2018 May. No abstract available.

PMID:
29748241
39.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
40.

Defining the best regimen to treat isoniazid-resistant tuberculosis.

Migliori GB, Tiberi S, Sotgiu G.

Lancet Respir Med. 2018 Apr;6(4):233-235. doi: 10.1016/S2213-2600(18)30079-1. No abstract available.

PMID:
29595499
41.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
42.

Predicting the effect of improved socioeconomic health determinants on the tuberculosis epidemic.

Migliori GB, Garcia-Basteiro AL.

Lancet Glob Health. 2018 May;6(5):e475-e476. doi: 10.1016/S2214-109X(18)30189-X. Epub 2018 Mar 23. No abstract available.

43.

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!

Tiberi S, Cabibbe AM, Tomlins J, Cirillo DM, Migliori GB.

EBioMedicine. 2018 Mar;29:11-12. doi: 10.1016/j.ebiom.2018.02.006. Epub 2018 Feb 8. No abstract available.

44.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB".

Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar;68:122-124. doi: 10.1016/j.ijid.2018.03.002. Epub 2018 Mar 22. No abstract available.

45.

The World Health Organization standards for tuberculosis care and management.

Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800098. doi: 10.1183/13993003.00098-2018. Print 2018 Mar. No abstract available.

PMID:
29567724
46.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

PMID:
29567721
47.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

PMID:
29567720
48.

New drugs and perspectives for new anti-tuberculosis regimens.

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24. Review.

49.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477. Review.

PMID:
29470252
50.

Adolescents and young adults: a neglected population group for tuberculosis surveillance.

García-Basteiro AL, Schaaf HS, Diel R, Migliori GB.

Eur Respir J. 2018 Feb 21;51(2). pii: 1800176. doi: 10.1183/13993003.00176-2018. Print 2018 Feb. No abstract available.

PMID:
29467211

Supplemental Content

Loading ...
Support Center